|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Cancer-associated mutation abolishes the impact of TRIM21 on the invasion of breast cancer cells.
|
31622717 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Traditional serrated adenoma (TSA) remains the least understood of all the colorectal adenomas, although these lesions have been associated with a significant cancer risk, twice that of the conventional adenoma (CAD) and of the sessile serrated adenoma (SSA/P).
|
31729028 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
More importantly, comparing to the xenograft tumors derived from MDA-MB-231 cells with the wild-type TRIM21, xenograft tumors derived from MDA-MB-231 cells with the R64Q mutated TRIM21 showed greatly increased infiltration into neighboring muscle fibers.
|
31622717 |
2020 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Traditional serrated adenoma (TSA) remains the least understood of all the colorectal adenomas, although these lesions have been associated with a significant cancer risk, twice that of the conventional adenoma (CAD) and of the sessile serrated adenoma (SSA/P).
|
31729028 |
2020 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases.
|
30915082 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This concept of cancer awareness training might be also applicable to other countries in SSA.
|
31707642 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
For cancer risk, industrial sources and SSA posed the highest proportion.
|
31655327 |
2019 |
|
Lupus Vulgaris
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with isolated anti-Ro52 had a wider variety of diseases associated, but among auto-immune diseases they were more prone to inflammatory myositis (OR 10.5 [1.4-81.7], <i>p</i> = 0.02) and inflammatory rheumatism (OR 4.6 [1.6-13.8], <i>p</i> = 0.006) in contrast to systemic lupus (OR 0.2 [0.1-0.3], <i>p</i> < 10<sup>-4</sup>) or primary Sjögren's syndrome (OR 0.1 [0.06-0.2], <i>p</i> < 10<sup>-4</sup>).
|
30915082 |
2019 |
|
Lupus Erythematosus, Discoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with isolated anti-Ro52 had a wider variety of diseases associated, but among auto-immune diseases they were more prone to inflammatory myositis (OR 10.5 [1.4-81.7], <i>p</i> = 0.02) and inflammatory rheumatism (OR 4.6 [1.6-13.8], <i>p</i> = 0.006) in contrast to systemic lupus (OR 0.2 [0.1-0.3], <i>p</i> < 10<sup>-4</sup>) or primary Sjögren's syndrome (OR 0.1 [0.06-0.2], <i>p</i> < 10<sup>-4</sup>).
|
30915082 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with isolated anti-Ro52 had a wider variety of diseases associated, but among auto-immune diseases they were more prone to inflammatory myositis (OR 10.5 [1.4-81.7], <i>p</i> = 0.02) and inflammatory rheumatism (OR 4.6 [1.6-13.8], <i>p</i> = 0.006) in contrast to systemic lupus (OR 0.2 [0.1-0.3], <i>p</i> < 10<sup>-4</sup>) or primary Sjögren's syndrome (OR 0.1 [0.06-0.2], <i>p</i> < 10<sup>-4</sup>).
|
30915082 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rowell syndrome (RS) is a rare disease characterized by the association of systemic lupus erythematosus (SLE) or cutaneous lupus with lesions similar to erythema multiforme and the presence of autoantibodies including ANA, SSA, SSB, or rheumatoid factor.
|
31674268 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We selected a core of an antiphospholipid syndrome-like SLE (aPL+ group; positive in the lupus anticoagulant (LA) test and negative for all three of SSA (Ro52 and Ro60) and SSB antibodies) and a Sjögren's syndrome-like SLE (SSA/SSB+ group; positive for all three of SSA (Ro52 and Ro60) and SSB antibodies but negative in the LA test).
|
30777133 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data support that nuclear PTMA protein serves as a tumor suppressor in bladder cancer through upregulating PTEN and orchestrating TRIM21 for the regulation of Nrf2 signaling.
|
30719818 |
2019 |
|
Congenital heart block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Benefits of fetal echocardiographic surveillance in pregnancies at risk of congenital heart block: single-center study of 212 anti-Ro52-positive pregnancies.
|
30620419 |
2019 |
|
Congenital heart block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Congenital heart block (CHB) may develop in fetuses of Ro/SSA autoantibody-positive women.
|
30808622 |
2019 |
|
Primary Sjögren's syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition to LSGB pattern, anti-SSA/Ro52-positivity, reduced C3 levels, hypoalbuminemia and anemia, also indicate significant association with renal involvement in pSS.
|
30411528 |
2019 |
|
Primary Sjögren's syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Infections were more prominently associated with the development of SSA/SSB autoantibody-positive pSS (OR 2.7, 95% CI 2.0-3.5).
|
30892751 |
2019 |
|
Primary Sjögren's syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary Sjögren's syndrome is associated with a markedly increased risk of cardiovascular disease and the presence of Ro/SSA and La/SSB autoantibodies identify the subgroup of patients carrying the highest risk.
|
31127862 |
2019 |
|
Primary Sjögren's syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mononuclear cell infiltration of exocrine glands, production of Ro/SSA and La/SSB autoantibodies, along with oral and ocular dryness, are characteristic features of primary Sjögren's syndrome (pSS).
|
31366407 |
2019 |
|
Primary Sjögren's syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of SSA and SSB Antibodies Associated with Primary Sjögren's Syndrome Using Enzyme-Linked Immunosorbent Assay.
|
30539582 |
2019 |
|
Primary Sjögren's syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
RF should be considered as a prognostic, but not diagnostic, factor in patients with pSS, as it is associated with more severe disease course (sicca eye symptoms, ESSDAI) and parameters (production of gammaglobulins, ANA, anti SS-A, anti-SS-B autoantibodies) indicating increased B cell activity.
|
30810912 |
2019 |
|
Primary Sjögren's syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Distinct clinical characteristics of anti-Ro/SSA-negative primary Sjögren's syndrome: data from a nationwide cohort for Sjögren's syndrome in Korea.
|
31376264 |
2019 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Congenital heart block (CHB) may develop in fetuses of Ro/SSA autoantibody-positive women.
|
30808622 |
2019 |
|
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-Ro-52 and anti-Scl-70 had increased values for predicting ILD in SSc patients, while anti-Ro-52 had increased values for predicting PAH in SSc patients.
|
30685360 |
2019 |
|
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
After controlling for the presence of myositis-specific autoantibodies, anti-Ro52 autoantibodies were associated with the presence of ILD (36% vs 4%, p<0.001).
|
31018961 |
2019 |